Pharmacological management of metastatic boney pain

Bibliography

• WEISS SC, EMANUEL LL, FAIRCLOUGH DL, EMANUEL EJ: Understanding the experience of pain in terminally ill patients. Lancet (2001) 357(9265):1311–1315.
   PubMed Web of Science ®Google Scholar
• ••A good starting point when trying to get togrips with the management of patients with metastatic cancer.
   Google Scholar
• WORLD HEALTH ORGANISATION: Cancer Pain Relief, with a guide to opioid availability (2nd edn). Geneva: World Health Organisation, 1996.
   Google Scholar
• COLEMAN R: New roles for bisphosphonates in cancer therapy. Progress Palliat. Care (1996) 4:39–43.
   Google Scholar
• EXPERT WORKING GROUP OF THE EUROPEAN ASSOCIATION FOR PALLIATIVE CARE: Morphine in cancer pain: modes of administration. Br. Med. (1996) 12:823–826.
   Google Scholar
• MIASKOWSKI C, MACK KA, DODD M et al.: Oncology outpatients with pain from bone metastasis require more than around-the-clock dosing of analgesics to achieve adequate pain control. Pain (2002) 3(1):12–20.
   Web of Science ®Google Scholar
• SCHOLES C, TROTMAN I: The theoretical basis of opioid rotation. CME Bull. Palliat. Med. (1998) 1:1.
   Google Scholar
• FALLON M: Opioid rotation: does it have a role? Palliat. Med. (1997) 11:177–178.
   Web of Science ®Google Scholar
• TWYCROSS R, WILCOCK A, THORP S: The Palliative Cam Formulary Radcliffe Medical Press, Oxford, UK (1998).
   Google Scholar
• MCDONALD C J, MILLER AJ: A comparative potency study of a controlled release tablet formulation of hydromorphone with controlled release morphine in patients with cancer pain. Abstracts of the Fifth Congress. Eur. Palliat. Care (1997).
   Google Scholar
• DE STOUTZ ND, BRUERA E, SUAREZ-ALMAZOR M: Opioid rotation for toxicity reduction in terminal cancer patients. I Pain Symptom Manage. (1995) 10:378–384.
   PubMed Web of Science ®Google Scholar
• •A good observational study from Edmonton demonstrating the benefits of opioid cycling by providing good symptom control whilst reducing opiate-related side effects.
   Google Scholar
• RIPAMONTI C, ZECCA E, BRUERA E: An update on the clinical use of methadone for cancer pain. Pain (1997) 70:109–115.
   PubMed Web of Science ®Google Scholar
• LIPTON A: Bisphosphonates and breastcarcinoma. Cancer (1997) 80\(Suppl. 8):1668–1673.
   Google Scholar
• •An excellent review article in cancer based on the Protocol 19 Aredia Breast Cancer Study Group data.
   Google Scholar
• SAAD F, GLEASON DM, MURRAY R et al., ZOLEDRONIC ACID PROSTATE CANCER STUDY GROUP: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Nati Cancer Inst. (2002) 94(19):1458–1468.
   PubMed Web of Science ®Google Scholar
• •An excellent study demonstrating the benefits of bisphosphonates in reducing adverse skeletal events and providing pain relief in skeletal metastases from prostate cancer.
   Google Scholar
• ADAMI S: Bisphosphonates in prostate cancer. Cancer (1997) 80\(Suppl. 8):1674–1679.
   Google Scholar
• ••This review article addresses the role ofbisphosphonates (clodronate) in skeletal meatastases from prostate cancer in providing pain relief and going on to look at why a drug aimed at osteodast-driven lesions should benefit osteoblast-driven lesions.
   Google Scholar
• URAL AU, YILMAZ MI, AVCU F et al.: The bisphosphonate zoledronic acid induces cytotoxicity in human myeloma cell lines with enhancing effects of dexamethasone and thalidomide. hat. Hematol. (2003) 78(5)443–449.
   Google Scholar
• •This is one of the first papers to suggest the antitumour activity of zoledronic acid.
   Google Scholar
• HORTOBAGYI GN, THERIAULT RL, PORTER L et al.: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl. Med. (1996) 335(24):1836–1837.
   PubMed Web of Science ®Google Scholar
• ROSEN LS, GORDON D, TCHEKMEDYIAN S et al.: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a Phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. j Clin. Oncol (2003) 21(16):3150–3157.
   PubMed Web of Science ®Google Scholar
• •An important paper, demonstrating the efficacy of zoledronic acid in managing pain and skeletal complications in non-breast and prostate metastases to the bone (primarily lung).
   Google Scholar
• GLOVER D, LIPTON A, KELLER A et al.: Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer (1994) 74(11):2949–2955.
   Google Scholar
• TUBIANA-HULIN M, BEUZEBOC P, MAURIAC L et al.: [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases] Bull. Cancer (2001) 88(7):701–707.
   Web of Science ®Google Scholar
• •A study demonstrating a reduction in adverse skeletal events and analgesic requirements in a double-blind, randomised trial set in France with 80 patients in each arm.
   Google Scholar
• KYLMALA T, TAMMELA TL, LINDHOLM TS, SEPPANEN J: The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer. Ann. Chir. Cynaecol. (1994) 83(4):316–319.
   PubMedGoogle Scholar
• VITALE G, FONDERICO F, MARTIGNETTI A et al.: Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. Br. J. Cancer (2001) 84(12):1586–1590.
   PubMed Web of Science ®Google Scholar
• RICHARDS MA: Advanced breast cancer: use of resources and cost implications. Br.Cancer (1993) 67:856–860.
   Google Scholar
• ROEMER-BECUWE C, VIGANO A, ROMANO F et al.: Safety of subcutaneous clodronate and efficacy in hypercalcaemia of malignancy: a novel route of administration. Pain Symptom Manage. (2003) 26(3):843–848.
   PubMed Web of Science ®Google Scholar
• FRANCIS MD, RUSSELL RG, FLEISCH H: Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 165:1264–1266.
   PubMed Web of Science ®Google Scholar
• FLEISCH H, RUSSELL RG, FRANCIS MD: Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 165:1262–1264.
   PubMed Web of Science ®Google Scholar
• SAHNI M, GUENTHER HL, FLEISCH H, COLLIN P, MARTIN TJ: Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. Clin. Invest. (1993) 91:2004–2011.
   Google Scholar
• HUGHES DE, WRIGHT KR, UY HL et al.: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J. Bone Miner: Res. (1995) 10:1478–1487.
   PubMed Web of Science ®Google Scholar
• FRITH JC, MONKKONEN J, BLACKBURN GM, RUSSELL RG, ROGERS MJ: Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichlormethylene) triphosphate, by mammalian cells in vitro. J. Bone Miner. Res. (1997) 12:1358–1367.
   PubMed Web of Science ®Google Scholar
• LUCKMAN SP, HUGHES DE, COXON FP et al.: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J. Bone Miner. Res. (1998) 13:581–589.
   PubMed Web of Science ®Google Scholar
• REED SD, RADEVA JI, GLENDENNING GA, SAAD F, SCHULMAN KA: Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. Urol. (2004) 171(4):1537–1542.
   Web of Science ®Google Scholar
• NHS EXECUTIVE: EL(96)85. A Policy Framework For Commissioning Cancer Services: Palliative Care Services. October (1996).
   Google Scholar
• ROYAL PHARMACEUTICAL SOCIETY OF GREAT BRITAIN: Pharmaceutical care of cancer patients in the community. Pharm. J. (1997) 258:54–57.
   Google Scholar
• CALMAN K, HINE J: A Policy Framework for Commissioning Cancer Services. Department of Health. April (1995).
   Google Scholar
• MUNDY GR: Mechanisms of bone metastasis. Cancer (1997) 80:1546–1556.
   PubMed Web of Science ®Google Scholar
• ••Mechanisms of bone metastasis andthe consequent therapeutic modalities are addressed.
   Google Scholar
• GOLTZMEN D: Mechanisms of the development of osteoblastic metastases. Cancer (1997) 80:1581–1587.
   PubMed Web of Science ®Google Scholar
• SATOR O: Radioisotopic treatment of bone pain from metastatic prostate cancer. Carr. Oncol. Rep. (2003) 5(3):258–262.
   PubMedGoogle Scholar
• URCH CE, DONOVAN-RODRIGUEZ T, DICKENSON AH: Alterations in dorsal horn neurones in a rat model of cancer induced bone pain. Pain (2003) 106(3):347–356.
   PubMed Web of Science ®Google Scholar
• CLOHISY DR, MANTYH PW: Bone cancer pain. Clin. Orthop. (2003) 415(Suppl.):S279–S288.
   Google Scholar
• MATA M, GLORIOSO J, FINK DJ: Development of HSV-mediated gene transfer for the treatment of chronic pain. Exp. Neurol. (2003) 184\(Suppl. 1):S25–S29.
   Google Scholar